← Back to patent-cliff list
LNK-01002
Tier C — Watch / tradeLNK-01002
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK1, JAK2, FLT3
Indications (approved)：Myelofibrosis, Myeloproliferative neoplasm, Haematological malignancy, Acute myeloid leukaemia, Essential thrombocythaemia, Polycythaemia vera
Regional status
US
Discontinued
2021-04-08
EU
-
China
Phase I
2020-12-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LNK-01002?
Approved indications include: Myelofibrosis, Myeloproliferative neoplasm, Haematological malignancy, Acute myeloid leukaemia, Essential thrombocythaemia, Polycythaemia vera.
When does the LNK-01002 patent expire?
No public expiry year is available for LNK-01002 yet; this page updates once verified.
How do I get a quote for LNK-01002 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22